^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

ALPPL2-targeted antibody-drug conjugate

Related drugs:
12ms
SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=43, Terminated, Seagen Inc. | Trial completion date: Nov 2027 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2023; Study closed due to portfolio prioritization
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
SGN-ALPV
1year
SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=43, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=305 --> 43
Enrollment closed • Enrollment change • Metastases
|
SGN-ALPV
almost3years
SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models (AACR 2022)
SGN-ALPV was well tolerated in non-human primates (NHP) and exhibited linear pharmacokinetic characteristics, with a toxicity profile consistent with other vedotin-based ADCs. In summary, differential expression of ALPP and ALPPL2 in the tumor versus normal tissue, antibody specificity, antitumor activity, and tolerability of SGN-ALPV provide a strong rationale for the initiation of a planned first-in-human Phase 1 clinical study.
Preclinical
|
ALPP (Alkaline Phosphatase, Placental) • ALPG (Alkaline Phosphatase)
|
ALPG expression
|
SGN-ALPV